Intense Put Option Trading Highlights Bearish Sentiment
On 7 May 2026, Lupin Ltd (NSE: LUPIN) recorded substantial activity in put options, particularly at strike prices of ₹2,400 and ₹2,300, both expiring on 26 May 2026. The ₹2,400 strike saw 2,337 contracts traded, generating a turnover of approximately ₹433.84 lakhs, while the ₹2,300 strike recorded 2,530 contracts with a turnover of ₹162.04 lakhs. Open interest at these strikes remains elevated, with 1,341 contracts at ₹2,400 and 1,329 at ₹2,300, indicating sustained investor interest in downside protection or speculative bearish bets.
The underlying stock closed at ₹2,417 on 7 May, just 2.97% shy of its 52-week high of ₹2,494. Despite this proximity to peak levels, Lupin’s stock price declined by 1.62% on the day, underperforming its sector by 1.54% and the broader Sensex by 0.98%. Intraday, the stock touched a low of ₹2,394.9, marking a 2.65% drop from the previous close. This price action, coupled with the surge in put option volumes, suggests that market participants are positioning for potential downside or increased volatility in the near term.
Technical and Market Context
Technically, Lupin remains in a strong uptrend, trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. However, the recent two-day rally was halted by profit-taking, as evidenced by the stock’s reversal on 7 May. Delivery volumes have also declined, with a 27.21% drop in delivery volume to 6.17 lakh shares compared to the five-day average, signalling waning investor participation despite the stock’s mid-cap liquidity profile. The average traded value supports sizeable trades up to ₹8.04 crore, ensuring ample liquidity for institutional and retail investors alike.
Implications of Put Option Activity
The heavy put option activity at strikes ₹2,400 and ₹2,300, both close to the current market price, indicates a strategic hedging approach by investors or outright bearish bets. Such positioning often reflects concerns over near-term catalysts, sector headwinds, or broader market corrections. Given Lupin’s strong Mojo Score of 87.0 and an upgraded Mojo Grade from Buy to Strong Buy as of 4 May 2026, this divergence between fundamental optimism and derivative market caution is noteworthy.
Investors may be using puts to protect gains accumulated during the recent rally or to speculate on a potential pullback. The expiry date of 26 May 2026 is critical, as it coincides with the end of the current monthly options cycle, often a period of heightened volatility and price discovery. The concentration of open interest near the money suggests that traders expect the stock to test these levels in the coming weeks.
Sector and Broader Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Lupin’s 1-day return of -1.42% contrasts with the sector’s marginal decline of -0.06%, underscoring relative weakness. The Sensex’s 0.64% drop further contextualises Lupin’s underperformance. This divergence may be driven by company-specific factors such as earnings outlook, regulatory developments, or competitive pressures, which are prompting investors to seek downside protection through options.
Investor Strategy and Outlook
For investors, the current put option activity serves as a cautionary signal. While Lupin’s fundamentals remain robust, with a market capitalisation of ₹1,10,883.99 crore and a strong buy rating, the derivative market’s bearish tilt suggests that risk management is prudent. Investors should monitor upcoming earnings announcements, regulatory updates, and sector trends closely. The stock’s proximity to its 52-week high also raises the possibility of profit booking or consolidation in the short term.
Traders with a bullish outlook might consider the elevated put option premiums as an opportunity to write options or implement covered call strategies, capitalising on the implied volatility. Conversely, those anticipating a correction may find the current strike prices and expiry dates suitable for protective puts or speculative positions.
Conclusion
Lupin Ltd’s recent surge in put option volumes at near-the-money strikes ahead of the 26 May expiry highlights a nuanced market sentiment. Despite strong fundamental ratings and a solid uptrend, investors are hedging against potential downside risks amid sector underperformance and price volatility. This dynamic underscores the importance of integrating derivative market signals with fundamental analysis to navigate the evolving landscape of mid-cap pharmaceutical stocks effectively.
